1.Prof.Yang Fan made a poster display with the theme of"Efficacy and toxicity for CD7 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory T-cell lymphoma".2.Prof.Li Zhihui made a poster display with the theme of"A real-world study of lenalidomide combined with low-dose venecla in maintenance therapy after allogeneic hematopoietic stem cell transplantation for recurrent and refractory hematological malignancies".3.Dr.Lin Yuehui made a poster display with the theme of"Combination of InotuzumabOzogamicin and Olverembatinib as Salvage Therapy for Elderly Patients with Relapsed and Refractory Ph+B-ALL".

1.By using chimeric antigen receptor T cell(CAR-T)bridging allogeneic hematopoietic stem cell transplantation(allo-HSCT)and targeted tyrosine kinase inhibitor(TKI)maintenance therapy,Dr.Song Yanzhi has increased the 2-year overall survival(OS)and disease-free survival(LFS)rates of R/R Ph+B-ALL patients to 79%.2.Aiming at the popular target of blood tumors-CD38,Dr.Li Zhihui explored in refractory/recurrent children with hematologic malignancies that recurred after allo-HSCT,and confirmed that the treatment regimen containing CD38 monoclonal antibody-Daretuzumab showed initial therapeutic feasibility and effectiveness for half of CD38-positive patients.

Prof.Tong Chunrong and Director Liu Shuangyou spoke at the Presidential Symposium on behalf of the team:"CD19-and CD22 CAR T Sequential Treatment of acute B lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation:With a median follow-up time of 10 months,the study was selected as one of the top six outstanding clinical abstracts from more than 1,000 reviews worldwide.Further clinical studies should be conducted to increase the number of cases and follow-up time:32 patients with B-ALL who relapsed after allogeneic hematopoietic stem cell transplantation were treated with CD19-and CD22 CAR-T sequential therapy.The median observation time was 10 months,and the complete response rate was 84.4%,the overall survival rate was 87.5%,and the minimal residual negative survival rate was 58.3%,which was the highest in the world.